AACR Annual Meeting 2019

Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth upon bevacizumab-induced hypoxia, in vivo

AACR Annual Meeting 2019

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting

AACR Annual Meeting 2019

Phase 2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma

AACR Annual Meeting 2019

Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of diffuse intrinsic pontine glioma (DIPG)

Society for NeuroOncology

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma

Society for NeuroOncology

Phase 1/2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma

Society for NeuroOncology

Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of diffuse intrinsic pontine glioma (DIPG)

Society for NeuroOncology

VAL-083 inhibits proliferation of a panel of eight glioblastoma stem cells: Downregulation of BRD4 as a novel anti-neoplastic mechanism

AACR Annual Meeting 2018

Dianhydrogalactitol (VAL-083) has a distinct mechanism of action that suggests combination with PARP inhibitors as an effective therapeutic strategy

AACR Annual Meeting 2018

Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of DIPG